Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.60 |
| ▸ | CCR5 | P51681 | 1/20 | 0.60 |
| ▸ | CCR8 | P51685 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | CSF1R | P07333 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | MET | P08581 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | CDK8 | P49336 | 1/20 | 0.58 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.58 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17051514 | 0.89 | CCR1 (0.75) | CCR1CCR5CCR8HDAC6AURKA | |
| SCHEMBL28873007 | 0.88 | AURKA (0.59) | CCR1CCR5CCR8HDAC6AURKA | |
| SCHEMBL15040982 | 0.88 | AURKA (0.58) | CCR1CCR5CCR8HDAC6AURKA | |
| SCHEMBL2477927 | 0.87 | CCR1 (0.71) | CCR1CCR5CCR8HDAC6AURKA | |
| SCHEMBL10000248 | 0.85 | CCR1 (0.68) | CCR1CCR5CCR8HDAC6AURKA | |
| SCHEMBL2480932 | 0.84 | CYP3A4 (0.50) | CCR1CCR5CCR8HDAC6AURKA | |
| SCHEMBL17230040 | 0.83 | CCR1 (0.46) | CCR1CCR5CCR8HDAC6AURKA | |
| SCHEMBL3771686 | 0.83 | CYP3A4 (0.49) | CCR1CCR5CCR8HDAC6AURKA | |
| SCHEMBL17051522 | 0.83 | CCR1 (0.65) | CCR1CCR5CCR8HDAC6AURKA | |
| SCHEMBL12846431 | 0.81 | CCR1 (0.62) | CCR1CCR5CCR8HDAC6AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11890604-B2 | Composite catalyst for carbon dioxide reduction and method of fabricating of the same | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS (KR) | 2024-02-06 | — | — | US | disclosed |
| US-20240002927-A1 | METHODS FOR DETECTION OF NUCLEOTIDE MODIFICATION | BLUECAT IP LIMITED (GB) | 2024-01-04 | — | — | US | disclosed |
| US-20230416815-A1 | METHOD FOR LABELING NUCLEIC ACID | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-12-28 | — | — | US | disclosed |
| EP-4240869-A1 | METHODS FOR DETECTION OF NUCLEOTIDE MODIFICATION | Bluecat IP Limited (GB) | 2023-09-13 | — | — | EP | disclosed |
| CN-116685694-A | Method for detecting nucleotide modifications | 蓝猫知识产权有限公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-4211262-A1 | METHOD FOR LABELING NUCLEIC ACID | Cambridge Enterprise Limited (GB) | 2023-07-19 | — | — | EP | disclosed |
| CN-116323603-A | Method for labeling nucleic acids | 剑桥实业有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-11390575-B2 | Isomerisation reaction | FIRMENICH SA (CH) | 2022-07-19 | — | — | US | disclosed |
| WO-2022096751-A1 | METHODS FOR DETECTION OF NUCLEOTIDE MODIFICATION | BLUECAT IP LIMITED (GB) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022053718-A1 | METHOD FOR LABELING NUCLEIC ACID | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2022-03-17 | — | — | WO | disclosed |
| US-20100144046-A1 | CYCLOMETALATED TRANSITION METAL COMPLEXES FOR MULTIPLEX ANALYTE DETECTION | BIO-RAD LABORATORIES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2010052625-A1 | PYRROLIDINES | PFIZER LIMITED (GB) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120793-A1 | Pyrrolidines | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| EP-2155765-A1 | BIPYRIDINE METAL COMPLEXES FOR USE AS LIGHT-EMITTING MATERIAL | SOLVAY (BE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009002423-A2 | POLYCYCLIC GUANINE DERIVATIVES AND USE THEREOF | SCHERING CORPORATION (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008148830-A1 | BIPYRIDINE METAL COMPLEXES FOR USE AS LIGHT-EMITTING MATERIAL | SOLVAY (BE) | 2008-12-11 | — | — | WO | disclosed |
| US-7332232-B2 | OLEDs utilizing multidentate ligand systems | UNIVERSAL DISPLAY CORPORATION (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332232-B2 | OLEDs utilizing multidentate ligand systems | UNIVERSAL DISPLAY CORPORATION (US) | 2008-02-19 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120793-A1 | Pyrrolidines | PTGER2, PTGDR2, PTGES2 | CCR1 2940/4885CCR5 2405/4885CCR8 3456/4885 |
| US-20230416815-A1 | METHOD FOR LABELING NUCLEIC ACID | ALKBH1, ALKBH2, NT5C3B | CCR1 4396/4885CCR5 2287/4885CCR8 3428/4885 |
| US-20100144046-A1 | CYCLOMETALATED TRANSITION METAL COMPLEXES FOR MULTIPLEX ANALYTE DETECTION | CAD, NCLN, CCL5 | CCR1 230/4885CCR5 48/4885CCR8 250/4885 |
| US-11390575-B2 | Isomerisation reaction | CYP3A4, CYP4A11, UGT1A10 | CCR1 433/4885CCR5 555/4885CCR8 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.